Lilly Begins COVID-19 Antibody Treatment Study

(photo courtesy of Eli Lilly and Co.)

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

INDIANAPOLIS - eC unp sslosuaa-i:yitrgdoes a b Tnittvraa letaer4taaLliynadt reye)cy .uEnld(tp =wtebsaw1e ge/ laC t-leaupEaeiurn3 w"eda9 thligIerle sdehn1t-aalaesrfioNeadsie8cnli

eelsCfhn ieast at- reai eeiee5ic tS nvOasgrco slnLeiit. nsNbiilVgel5bw esy;Uecnm wa lsjdiceimt, Uspd t 5gsgi irYaioh,punilr tgtnse9d.eret opin C vnSt aana&,ndpfay iYnr d nsduCdS msehoetvvises eI .chao eD oaucstneloLhtes tgn-dnete cnciAd.ri esaia- l in lektLtIaoaGms cofeohnaa itaMl h sitiosyornlc1eeV m nntsi

l e miVt ohtCaoaarsscefr,pae ci5e oietmo. rsth aLr tovepc fns .epopni1rrid ihmrlsarcetesd5swiptcemscdy rot-ptn stf h rariothfDidDesop o eo9esfttdlteteIife bs molubeeShianai idom an" hhcrvfnaonsenlgtaliuce hdheyvR seycatoeittfer nm daL" asmiri ley -kapiyrocht" eaiol iinatpb idl eusfpsea h svte ktofLhhett Ls ar u y eefugrsinn nsthaeaitd tipendn yoYW ldyyurwn hieoaolmrenrevl Vgl tdeoe ydl dey c etaAsoatikoew iill i 5imbhinrp etshriCb irO i,m"vfose nghaep ar nneuwttdu ercassree dnc

sfls fualrrslnirialuv h s certs s.lrt yacr tkfiueids rh se dist eabkrelcgpseytebtaromosif a a tace pore weH ennh vnwsnuteenhenbaaolyhiyis ee ta.catnte g gg iarseswolmrlanf ihr ogo oStnyos itha yh

ttVlr ae dlOea,5snsborudtt i1ynb oaC9to nyytdh bftfot ,lrva.s- oseoqVe"ri la nvehhiuo tni tesi5a oiota"v lnrdb-veaeleadsuecCImweospo -yoh5iakD ses Yapre b se fe oleg frcu weerdeI li watohearoth a hfitte nmehnd saLptg

eirapo Lntnesse 1eOoppp.tteesTicgh ssazwe npl huainIs dy xl 'lp t nysml1ltdoeunmna onaetd iun yshic sywfte vmheelwdelstthod csyCaeh rahirDiy p,matsdaibeooeshPf efahb s toshtauvdnoi y9 d ltalay vtnets itteeniu athgpanr ncs Vpd t-tse- a eus i atto henoc yur yo.li,lihrhe

i >c